Trinity biotech announces increased orders for trinscreen hiv and raises guidance for 2024 sales

Dublin, ireland, aug. 26, 2024 (globe newswire) -- trinity biotech plc (nasdaq: trib), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has received substantial additional orders for trinscreen hiv. as a result of this strong demand and the successful scaling of production capacity, the company is now increasing its expected 2024 sales revenue for trinscreen hiv to approximately $10 million, up from $8 million previously.
TRIB Ratings Summary
TRIB Quant Ranking